Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

RatÀÇ ¹æ»ç¼± Á¶»ç¼º ±¸³»¿°¿¡ ´ëÇÑ Recombinant Human Epidermal Growth Factor (rhEGF)ÀÇ È¿°ú Effects of Recombinant Human Epidermal Growth Factor (rhEGF) on Experimental Radiation-Induced Oral Mucositis in Rats

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2006³â 24±Ç 1È£ p.67 ~ 76
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤±ÇÀÏ/Jung KI ±è¼±Èñ/¹®¼ö¿µ/±è¿¬È­/È«ÁØÇ¥/±èÇö¼÷/ÀÌ»ó¿í/Kim SH/Moon SY/Kim YW/Hong JP/Kim HS/Lee SW

Abstract

¸ñ Àû: ±¸³»¿°Àº µÎ°æºÎÁ¾¾çÀÌ ÀÖ´Â ¾ÏȯÀÚ¿¡°Ô ¹æ»ç¼± ¹× Ç×¾ÏÁ¦ Ä¡·á ½Ã¼ú ½Ã ¸Å¿ì ÈçÇÏ°Ô ¹ß»ýÇÏ´Â ÇÕº´ÁõÀÌ´Ù. º» ¿¬±¸´Â RatÀÇ ¹æ»ç¼±¼º ±¸³»¿° ¸ðµ¨¿¡¼­ recombinant human epidermal growth factor (rhEGF)ÀÇ È¿°ú¸¦ Æò°¡ÇÏ°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 25 GyÀÇ ¹æ»ç¼±·®À¸·Î µÎºÎ¿¡ ´Üȸ Á¶»çÇÑ Rat¸¦ ¹«ÀÛÀ§·Î 7¸¶¸®¾¿ ¹«Ã³Ä¡±º, ºÎÇüÁ¦ óġ±º, rhEGF 15 ¶Ç´Â 30¥ìg/day ±¸°­ ³» óġ±ºÀ¸·Î ³ª´©¾úÀ¸¸ç, ¹æ»ç¼±À» Á¶»çÇÏÁö ¾ÊÀº 7¸¶¸®ÀÇ Rat¸¦ Á¤»ó½ÃÇ豺À¸·Î ³ª´©¾ú´Ù. rhEGF ½Ã·á ¹× ºÎÇüÁ¦´Â 1ÀÏ 3ȸ RatÀÇ ±¸°­Á¡¸·¿¡ ¸ÅÀÏ µµÆ÷ÇÏ¿´´Ù. RatÀÇ »ýÁ¸À², üÁߺ¯È­ ¹× »ç·á¼·Ãë·®À» 18ÀÏ µ¿¾È °üÂûÇÏ¿´À¸¸ç, ¹æ»ç¼± Á¶»ç ÈÄ 7ÀÏ ¹× 18ÀÏ°¿¡ RatÀÇ ±¸°­Á¡¸·À» Á¶Á÷ÇÐÀûÀ¸·Î Æò°¡ÇÏ¿´´Ù.

°á °ú: ½ÇÇèÁ¾·á ½ÃÁ¡¿¡¼­ rhEGF 15 ¶Ç´Â 30¥ìg/day ±¸°­ ³» óġ±ºÀÌ ¸ðµÎ 33%ÀÇ »ýÁ¸À²À» º¸ÀÎ °Í¿¡ ºñÇÏ¿©, ¹«Ã³Ä¡±º ¹× ºÎÇüÁ¦ óġ±ºÀº ¸ðµÎ 0%ÀÇ »ýÁ¸À²À» º¸¿´´Ù. üÁߺ¯È­¿¡¼­µµ rhEGF óġ±ºÀº ¹æ»ç¼± Á¶»ç ÈÄ 2ÀϺÎÅÍ 7ÀϱîÁö ºÎÇüÁ¦ óġ±º¿¡ ºñÇÏ¿© RatÀÇ Æò±ÕüÁßÀÌ Åë°èÀûÀ¸·Î ´õ¿í ¹«°Å¿ü´Ù. »ç·á¼·ÃëÀ²Àº ¸ðµç ½ÃÇ豺¿¡¼­ ¹æ»ç¼± Á¶»ç ÈÄ 4ÀϱîÁö °¨¼ÒÇÏ´Â ¾ç»óÀ» º¸ÀÌ´Ù°¡, rhEGF 15 ¶Ç´Â 30¥ìg/day ±¸°­ ³» óġ±º¿¡¼­ 14ÀÏ°¿¡ ¶Ñ·ÇÇÑ »ç·á¼·ÃëÀ²ÀÇ Áõ°¡°¡ °üÂûµÇ¾ú´Ù. ¹æ»ç¼± Á¶»ç ÈÄ 7ÀÏ°ÀÇ Á¶Á÷ÇÐÀû ºÐ¼® °á°ú, rhEGF 15 ¶Ç´Â 30¥ìg/day ±¸°­³» óġ±ºÀÇ Rat¿¡¼­´Â Á¡¸· Ç¥ÇÇÃþÀÇ °¢Áú¼¼Æ÷ÀÇ Á¾Ã¢ ¹× º¯¼º¸¸ÀÌ °üÂûµÇ¾ú´ø °Í¿¡ ºñÇÏ¿©, ¹«Ã³Ä¡±º ¹× ºÎÇüÁ¦ óġ±º¿¡¼­´Â ½ÉÇÑ À§¸·¼º ¶Ç´Â ±Ë¾ç¼º ±¸³»¿°ÀÌ °üÂûµÇ¾ú´Ù.

°á ·Ð: rhEGF (15 ¶Ç´Â 30¥ìg/day ±¸°­ ³» óġ±º) óġ¿¡¼­ ¹æ»ç¼± Á¶»ç·Î À¯¹ß½ÃŲ RatÀÇ ±¸³»¿° ¸ðµ¨¿¡¼­ À¯ÀǼº ÀÖ´Â Ä¡À¯ È¿°ú¸¦ È®ÀÎÇÏ¿´À¸¸ç, º» ½ÃÇè°á°ú·Î rhEGF°¡ ¹æ»ç¼±¿¡ ÀÇÇØ À¯¹ßµÈ ±¸³»¿°À» Ä¡·áÇÒ ¼ö ÀÖ´Â ÀÓ»óÁ¦Á¦·Î½áÀÇ °¡´É¼ºÀ» º¼ ¼ö ÀÖ¾ú´Ù.

Purpose: Oral mucositis is a common toxicity of radiation or chemotherapy, which is used a treatment for head and neck cancer. We investigated effects of recombinant human epidermal growth factor (rhEGF) on radiation-induced oral mucositis in rat model.

Materials and Methods: Spraque-Dawley rats (7 per group) exposed to a single dose of 25 Gy (day 0) on their head, except for one group, were randomly divided into un-treated, vehicle-treated, and two rhEGF-treated groups. Rats were topically applied with rhEGF (15 or 30¥ìg/oral cavity/day) or vehicle to their oral mucosa. Survival rate of rats, weight changes, and food intakes were examined from day 0 to 18 after radiation. Histology study was performed from oral mucosa of rats at day 7 and 18 after radiation.

Results: rhEGF-treated groups (15 or 30¥ìg/day) showed all survival rate 33%, whereas un-treated and vehicle-treated groups showed all survival rate 0% at the end of experiment. rhEGF-treated groups statistically had less weight loss compared to vehicle-treated group from day 2 to 7 after radiation. Food intake of rats with rhEGF treatment turned to increase at day 14 after radiation. At 7 day after radiation, un-treated and vehicle-treated groups showed severe pseudomembraneous or ulcerative oral mucositis. On the other hand, rhEGF-treated groups had no more than cellular swelling and degeneration of epidermal cells in oral mucosa of rats.

Conclusion: These results suggest that rhEGF has significantly positive effects on radiation-induced oral mucositis in rats. rhEGF display a therapeutic potential on a clinical level.

Å°¿öµå

±¸³»¿°;¹æ»ç¼±;Rat ¸ðµ¨;Oral mucositis;Radiation;Epidermal growth factor;Rat model

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS